Drug Profile
Research programme: nano-particle based therapeutics - Topas Therapeutics/Elli Lilly
Alternative Names: Nano-particle based peptide therapeutics - Topas TherapeuticsLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Topas Therapeutics
- Class Anti-inflammatories; Immunotherapies; Peptide fragments; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Multiple sclerosis
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany
- 28 Apr 2020 No recent reports of development identified for research development in Autoimmune-disorders in Germany
- 28 Apr 2020 No recent reports of development identified for research development in Inflammation in Germany